

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): October 3, 2019 (September 27, 2019)**

**Alynlam Pharmaceuticals, Inc.**

(Exact Name of Registrant as Specified in Charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**001-36407**  
(Commission  
File Number)

**77-0602661**  
(IRS Employer  
Identification No.)

**675 West Kendall Street,  
Henri A. Termeer Square  
Cambridge, Massachusetts**  
(Address of Principal Executive Offices)

**02142**  
(Zip Code)

**Registrant's telephone number, including area code: (617) 551-8200**

**300 Third Street, Cambridge, Massachusetts 02142**  
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol(s)	Name of Each Exchange on Which Registered
Common Stock, \$0.01 par value per share	ALNY	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

**Item 8.01. Other Events.**

On September 27, 2019, Alnylam U.S., Inc. (“Alnylam U.S.”) repaid in full the \$30 million outstanding principal amount under the credit agreement among Alnylam U.S., as borrower, Alnylam Pharmaceuticals, Inc., as a guarantor, and Wells Fargo Bank, National Association, as the lender (the “Credit Agreement”). The Credit Agreement, which was scheduled to mature on April 29, 2021, terminated in accordance with its terms upon repayment of the outstanding indebtedness.

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ALNYLAM PHARMACEUTICALS, INC.

Date: October 3, 2019

By: /s/ Jeff Poulton

Jeff Poulton

Executive Vice President, Chief Financial Officer

0001178670 2019-09-27 2019-09-27 0001178670 dei:FormerAddressMember 2019-09-27 2019-09-27 false 0001178670 8-K 2019-09-27 Alnylam  
Pharmaceuticals, Inc. DE 001-36407 77-0602661 675 West Kendall Street Henri A. Termeer Square Cambridge MA 02142 617 551-8200 300  
Third Street Cambridge MA 02142 false false false false Common Stock, \$0.01 par value per share ALNY NASDAQ false